| 摘要 |
The present invention relates to new antagonists of the A2B adenosine recept or represented by formula (I). Those compounds are useful for treating a subjec t afflicted with a pathological condition or disease susceptible to ameliorati on by antagonism of the A2B adenosine receptor such as asthma, bronchoconstriction, allergic diseases, hypertension, atherosclerosis, reperfusion injury, myocardial ischemia, retinopathy, inflammation, gastrointestinal tract disorders, cell proliferation disorders, diabetes mellitus, and/or autoimmune diseases.
|
